Enhanced Curcumin Compositions and Methods for NK3 Antagonism
Legal Citation
Summary of the Inventive Concept
Improved curcumin compositions and methods for NK3 antagonism, enhancing bioavailability, solubility, and stability, and providing targeted and sustained delivery to treat NK3 receptor-mediated disorders.
Background and Problem Solved
The original patent identified curcumin compositions as NK3 antagonists, but limitations included poor bioavailability, solubility, and stability. The new inventive concept addresses these limitations by enhancing bioavailability, improving solubility and stability, and providing targeted and sustained delivery.
Detailed Description of the Inventive Concept
The inventive concept comprises methods and compositions that enhance the NK3 antagonistic properties of curcumin. New formulations improve bioavailability by at least 20%, and nanoparticle carriers target the central nervous system, releasing curcumin in a sustained manner over 24 hours. Combinations of diferuloylmethane and tetrahydrocurcumin in a 3:2 ratio exhibit improved solubility and stability. Pharmaceutical formulations with optimized excipients further enhance oral bioavailability by at least 30%. These improvements enable effective treatment of NK3 receptor-mediated disorders and prevention of neurokinin-B-induced inflammation.
Novelty and Inventive Step
The new inventive concept introduces novel formulations, delivery systems, and pharmaceutical formulations that significantly improve the performance of curcumin as an NK3 antagonist, overcoming the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include varying the ratio of diferuloylmethane to tetrahydrocurcumin, using different nanoparticle carriers or excipients, or combining curcumin with other NK3 antagonists. Variations may also include different routes of administration, such as injectable or transdermal delivery.
Potential Commercial Applications and Market
The enhanced curcumin compositions and methods have significant commercial potential in treating NK3 receptor-mediated disorders, such as neurological and psychiatric conditions, and may also be used in the prevention of neurokinin-B-induced inflammation. Target industries include pharmaceutical, nutraceutical, and biotechnology companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/9066 |
| A | A61 | A61K31/26 |
| A | A61 | A61K36/82 |
| A | A61 | A61P15/12 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions, specifically neuropharmacology and natural product-based drug delivery systems focusing on NK3 receptor antagonists and curcumin-based formulations
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or pharmacologist with expertise in natural product chemistry, drug formulation, nanoparticle delivery systems, and receptor pharmacology, holding an advanced degree with 3-5 years of specialized research experience
Obviousness Rationale
A PHOSITA would recognize that the PTD represents predictable incremental improvements to the source patent's curcumin composition, utilizing standard pharmaceutical engineering techniques to enhance bioavailability, stability, and targeted delivery. The variations represent routine optimization strategies well-known in drug formulation research, applying established methods like nanoparticle encapsulation and excipient selection to improve the fundamental NK3 antagonist composition disclosed in the original patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,594 |
|---|---|
| Title | Curcumin compositions and methods of use as an NK3 antagonist |
| Assignee(s) | JDS Therapeutics, LLC |